论文部分内容阅读
肠易激综合征(irritable bowel syndrome,IBS)是一种常见的功能性肠道疾病。其患病率呈逐年上升趋势,具有病程长,难治愈,易复发等特征,严重影响患者的生活质量。IBS发病机制尚不明确,目前尚无最佳治疗方案,因此,明确IBS的病因和发病机制是治疗IBS的首要任务。目前学术界研究表明,肥大细胞显著影响IBS的发生发展,其释放的活性物质在IBS病理生理变化过程中发挥关键性作用。该文对肥大细胞在IBS发生发展中的作用研究进展作一综述,为明确IBS发病机制,探索新的治疗靶点及开发新型治疗药物提供有价值的参考依据和新思路。
Irritable bowel syndrome (IBS) is a common functional bowel disease. The prevalence is rising year by year, with longer duration, difficult to cure, easy to relapse and other characteristics, seriously affecting the quality of life of patients. The pathogenesis of IBS is not clear, there is no optimal treatment plan, therefore, a clear understanding of the etiology and pathogenesis of IBS is the primary task of treatment of IBS. The current academic research shows that mast cells significantly affect the occurrence and development of IBS, the release of active substances in the pathophysiology of IBS play a key role. This review summarizes the research progress of the role of mast cells in the development of IBS and provides valuable reference and new ideas for clarifying the pathogenesis of IBS, exploring new therapeutic targets and developing new therapeutic drugs.